Lung Therapeutics has concluded the Phase Ia clinical trial of its Caveolin-1-related peptide, LTI-03, intended for the treatment of idiopathic pulmonary fibrosis (IPF).

A seven amino acid peptide, LTI-03, addresses hindrance of pro-fibrotic signalling and key epithelial cell survival.

The company noted that LTI-03 is a dry powder formulation intended for direct-to-lung administration.

The trial evaluated ascending doses of LTI-03 in healthy subjects. 

According to the findings from the trial, dose levels ranging from 2.5mg to 10mg of LTI-03 were demonstrated to be safe and well-tolerated.

Furthermore, no study discontinuations or serious adverse events were reported in this trial. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Lung Therapeutics president and CEO Brian Windsor said: “We are pleased that LTI-03 has passed this important safety milestone as we continue development. 

“We believe that the mechanism LTI-03 is unique among drugs in development for IPF, and we are excited to move LTI-03 into the next stage of clinical development in IPF patients later this year.”

The company noted that LTI-03 performed well at dose levels equivalent to a human dose ranging from 1 to 10mg in preclinical animal and ex-vivo models.

In addition, these preclinical data showed that the treatment with LTI-03 hindered pro-fibrotic signalling and preserved critical alveolar epithelial type 2 (AEC2) cells in the lungs.

Lung Therapeutics and Taiho Pharmaceutical signed an exclusive license agreement in November 2020 for a recombinant human single-chain urokinase plasminogen activator, LTI-01, in Japan.

In March 2017, the company commenced subject enrolment and dosing in a Phase Ia/b trial of LTI-01 to treat patients with loculated pleural effusions in Australia and New Zealand.